Trial · NCT00809848
Safety and Efficacy of AGN 210669 Ophthalmic Solution in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma
NCT00809848, Phase 1, Phase 2, Completed, Allergan; results first posted 2013-10-18
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Safety and Efficacy of AGN 210669 Ophthalmic Solution in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma. Trials, record NCT00809848. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00809848
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Safety and Efficacy of AGN 210669 Ophthalmic Solution in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma
- NCT number
- NCT00809848
- Status
- Completed
- Phases
- Phase 1, Phase 2
- Enrollment
- 172 participants, actual
- Lead sponsor
- Allergan
- Conditions
- Ocular Hypertension, Glaucoma
- Interventions
- AGN-210669 ophthalmic solution, 0.075%, AGN-210669 ophthalmic solution, 0.05%, AGN-210669 ophthalmic solution, 0.025%, bimatoprost ophthalmic solution 0.03%, AGN-210669 vehicle ophthalmic solution
- First posted
- 2008-12-17
- Last updated
- 2013-10-18
- Results first posted
- 2013-10-18
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change From Baseline in Average Eye Intraocular Pressure (IOP) | Baseline, Day 14 Hour 0 | IOP is a measurement of the fluid pressure inside the eye. The average of the 2 eyes is used for the analyses. A negative number change from baseline indicates a reduction in IOP (improvement) and a positive number change from baseline indicates an increase in IOP (worsening). |
| Secondary | Percentage of Patients With ≥ 20% Reduction From Baseline in Diurnal IOP | Baseline, Day 14 | IOP is a measurement of the fluid pressure inside the eye. Diurnal IOP is the average of the IOP values of both eyes at each time point measured at protocol-specified times throughout the day. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change From Baseline in Average Eye Intraocular Pressure (IOP) | Baseline, Day 14 Hour 0 | Modified Intent to Treat: all randomized and treated patients who had at least a baseline visit and 1 postbaseline IOP evaluation | Millimeters of Mercury (mmHg) | MEAN |
| SECONDARY | Percentage of Patients With ≥ 20% Reduction From Baseline in Diurnal IOP | Baseline, Day 14 | Modified Intent to Treat: all randomized and treated patients who had at least a baseline visit and 1 postbaseline IOP evaluation | Percentage of Patients | NUMBER |
Source ClinicalTrials.gov
Results by group15
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline in Average Eye Intraocular Pressure (IOP) | AGN-210669 Ophthalmic Solution, 0.075% | Baseline - Hour 0 | 25.350 | Standard Deviation 2.8018 | Millimeters of Mercury (mmHg) |
| Change From Baseline in Average Eye Intraocular Pressure (IOP) | AGN-210669 Ophthalmic Solution, 0.05% | Baseline - Hour 0 | 25.318 | Standard Deviation 2.9377 | Millimeters of Mercury (mmHg) |
| Change From Baseline in Average Eye Intraocular Pressure (IOP) | AGN-210669 Ophthalmic Solution, 0.025% | Baseline - Hour 0 | 25.341 | Standard Deviation 2.6375 | Millimeters of Mercury (mmHg) |
| Change From Baseline in Average Eye Intraocular Pressure (IOP) | Bimatoprost Ophthalmic Solution 0.03% | Baseline - Hour 0 | 24.650 | Standard Deviation 2.0622 | Millimeters of Mercury (mmHg) |
| Change From Baseline in Average Eye Intraocular Pressure (IOP) | AGN-210669 Vehicle Ophthalmic Solution | Baseline - Hour 0 | 25.507 | Standard Deviation 2.9004 | Millimeters of Mercury (mmHg) |
| Change From Baseline in Average Eye Intraocular Pressure (IOP) | AGN-210669 Ophthalmic Solution, 0.075% | Change from Baseline at Day 14 - Hour 0 | -5.807 | Standard Deviation 3.7007 | Millimeters of Mercury (mmHg) |
| Change From Baseline in Average Eye Intraocular Pressure (IOP) | AGN-210669 Ophthalmic Solution, 0.05% | Change from Baseline at Day 14 - Hour 0 | -5.197 | Standard Deviation 3.1947 | Millimeters of Mercury (mmHg) |
| Change From Baseline in Average Eye Intraocular Pressure (IOP) | AGN-210669 Ophthalmic Solution, 0.025% | Change from Baseline at Day 14 - Hour 0 | -4.068 | Standard Deviation 2.8520 | Millimeters of Mercury (mmHg) |
| Change From Baseline in Average Eye Intraocular Pressure (IOP) | Bimatoprost Ophthalmic Solution 0.03% | Change from Baseline at Day 14 - Hour 0 | -6.575 | Standard Deviation 3.2184 | Millimeters of Mercury (mmHg) |
| Change From Baseline in Average Eye Intraocular Pressure (IOP) | AGN-210669 Vehicle Ophthalmic Solution | Change from Baseline at Day 14 - Hour 0 | -2.382 | Standard Deviation 2.9396 | Millimeters of Mercury (mmHg) |
1 to 10 of 15Source ClinicalTrials.gov
See all 15 results by groupParticipant flow15
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | AGN-210669 Ophthalmic Solution, 0.075% | 36 | |
| Overall Study | STARTED | AGN-210669 Ophthalmic Solution, 0.05% | 34 | |
| Overall Study | STARTED | AGN-210669 Ophthalmic Solution, 0.025% | 34 | |
| Overall Study | STARTED | Bimatoprost Ophthalmic Solution 0.03% | 31 | |
| Overall Study | STARTED | AGN-210669 Vehicle Ophthalmic Solution | 37 | |
| Overall Study | COMPLETED | AGN-210669 Ophthalmic Solution, 0.075% | 36 | |
| Overall Study | COMPLETED | AGN-210669 Ophthalmic Solution, 0.05% | 34 | |
| Overall Study | COMPLETED | AGN-210669 Ophthalmic Solution, 0.025% | 34 | |
| Overall Study | COMPLETED | Bimatoprost Ophthalmic Solution 0.03% | 30 | |
| Overall Study | COMPLETED | AGN-210669 Vehicle Ophthalmic Solution | 34 |
1 to 10 of 15Source ClinicalTrials.gov
See all 15 participant flowAdverse events40
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Conjunctival Hyperaemia | Eye disorders | AGN-210669 Ophthalmic Solution, 0.075% | 10 | 36 | |
| other | Conjunctival Hyperaemia | Eye disorders | AGN-210669 Ophthalmic Solution, 0.05% | 11 | 34 | |
| other | Conjunctival Hyperaemia | Eye disorders | AGN-210669 Ophthalmic Solution, 0.025% | 5 | 34 | |
| other | Conjunctival Hyperaemia | Eye disorders | Bimatoprost Ophthalmic Solution 0.03% | 12 | 31 | |
| other | Conjunctival Hyperaemia | Eye disorders | AGN-210669 Vehicle Ophthalmic Solution | 3 | 37 | |
| other | Photophobia | Eye disorders | AGN-210669 Ophthalmic Solution, 0.075% | 3 | 36 | |
| other | Photophobia | Eye disorders | AGN-210669 Ophthalmic Solution, 0.05% | 0 | 34 | |
| other | Photophobia | Eye disorders | AGN-210669 Ophthalmic Solution, 0.025% | 0 | 34 | |
| other | Photophobia | Eye disorders | Bimatoprost Ophthalmic Solution 0.03% | 0 | 31 | |
| other | Photophobia | Eye disorders | AGN-210669 Vehicle Ophthalmic Solution | 0 | 37 |
1 to 10 of 40Source ClinicalTrials.gov
See all 40 adverse eventsAdverse event totals15
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | AGN-210669 Ophthalmic Solution, 0.075% | ||
| Total, all-cause mortality | AGN-210669 Ophthalmic Solution, 0.05% | ||
| Total, all-cause mortality | AGN-210669 Ophthalmic Solution, 0.025% | ||
| Total, all-cause mortality | Bimatoprost Ophthalmic Solution 0.03% | ||
| Total, all-cause mortality | AGN-210669 Vehicle Ophthalmic Solution | ||
| Total, other adverse events | AGN-210669 Ophthalmic Solution, 0.075% | 17 | 36 |
| Total, other adverse events | AGN-210669 Ophthalmic Solution, 0.05% | 18 | 34 |
| Total, other adverse events | AGN-210669 Ophthalmic Solution, 0.025% | 9 | 34 |
| Total, other adverse events | Bimatoprost Ophthalmic Solution 0.03% | 20 | 31 |
| Total, other adverse events | AGN-210669 Vehicle Ophthalmic Solution | 5 | 37 |
1 to 10 of 15Source ClinicalTrials.gov
See all 15 adverse event totalsPapers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00809848
GET https://conductscience.org/api/trials/v1/NCT00809848/events?page=2